

FILE 'HOME' ENTERED AT 13:42:18 ON 14 AUG 2007

=> file ca

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'CA' ENTERED AT 13:42:30 ON 14 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2007 VOL 147 ISS 8

FILE LAST UPDATED: 9 Aug 2007 (20070809/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.45

0.66

FILE 'REGISTRY' ENTERED AT 13:42:54 ON 14 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 13 AUG 2007 HIGHEST RN 944501-68-2

DICTIONARY FILE UPDATES: 13 AUG 2007 HIGHEST RN 944501-68-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s azithromycin

L1 17 AZITHROMYCIN

=> file ca  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.40	6.06

FULL ESTIMATED COST

FILE 'CA' ENTERED AT 13:43:08 ON 14 AUG 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2007 VOL 147 ISS 8  
FILE LAST UPDATED: 9 Aug 2007 (20070809/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1  
L2 3391 L1

=> s l2 and lyophilized  
14679 LYOPHILIZED  
L3 6 L2 AND LYOPHILIZED

=> d l3 1-6

L3 ANSWER 1 OF 6 CA COPYRIGHT 2007 ACS on STN  
AN 147:79396 CA  
TI Process for the purification of macrolide antibiotics  
IN De Tommaso, Vincenzo  
PA Pharmatex Italia S.r.l., Italy  
SO PCT Int. Appl., 7pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007068644	A1	20070621	WO 2006-EP69414	20061207
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,			

KG, KZ, MD, RU, TJ, TM  
EP 1798237 A1 20070620 EP 2005-112283 20051216  
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
BA, HR, MK, YU

PRAI EP 2005-112283 A 20051216  
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 6 CA COPYRIGHT 2007 ACS on STN  
AN 145:69954 CA  
TI Azithromycin lyophilized powder for injection  
IN Wei, Shuhui; Guo, Weiqin; Zhang, Yu; Sun, Peng; Zhi, Caihui  
PA Ouyi Pharmaceutical Co., Ltd., Shijiazhuang Pharmaceutical Group, Peop.  
Rep. China  
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 10 pp.  
CODEN: CNXXEV  
DT Patent  
LA Chinese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1723910	A	20060125	CN 2005-10014275	20050630
PRAI	CN 2005-10014275		20050630		

L3 ANSWER 3 OF 6 CA COPYRIGHT 2007 ACS on STN  
AN 145:14751 CA  
TI Lyophilized azithromycin formulation  
IN Woo, Byung Ho; Kwok, K. Keith; Yang, Kang Yong  
PA American Pharmaceutical Partners, Inc., USA  
SO U.S. Pat. Appl. Publ., 14 pp., Cont. of Appl. No. PCT/US05/014369.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006116336	A1	20060601	US 2005-225767	20050913
	US 2005209172	A1	20050922	US 2004-802282	20040317
	WO 2006115494	A1	20061102	WO 2005-US14369	20050426
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2004-802282	A2	20040317		
	WO 2005-US14369	A1	20050426		

L3 ANSWER 4 OF 6 CA COPYRIGHT 2007 ACS on STN  
AN 144:94346 CA  
TI Oral delivery system comprising a drug/polymer complex  
IN Dong, Liang-Chang; Han, Jasmine E.; Pollock-Dove, Crystal; Wong, Patrick  
S. L.  
PA USA  
SO U.S. Pat. Appl. Publ., 23 pp.  
CODEN: USXXCO  
DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005287212	A1	20051229	US 2005-148673	20050608
	CA 2571554	A1	20060119	CA 2005-2571554	20050608
	WO 2006007354	A2	20060119	WO 2005-US20356	20050608
	WO 2006007354	A3	20060427		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP	1761265	A2	20070314	EP 2005-757711	20050608
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	US 2004-583816P	P	20040628		
	WO 2005-US20356	W	20050608		

L3 ANSWER 5 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 143:312016 CA

TI Lyophilized azithromycin formulation

IN Woo, Byung Ho; Kwok, K. Keith; Yang, Kang Yong

PA American Pharmaceutical Partners, Inc., USA

SO U.S. Pat. Appl. Publ., 14 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005209172	A1	20050922	US 2004-802282	20040317
	US 2006116336	A1	20060601	US 2005-225767	20050913
PRAI	US 2004-802282	A2	20040317		
	WO 2005-US14369	A1	20050426		

L3 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 136:139859 CA

TI Manufacturing clear liquid pharmaceutical composition of azithromycin

IN Khamar, Bakulesh Mafatlal; Gumudavelli, Sridhar Krishnamurthy

PA Cadila Pharmaceuticals Limited, India

SO PCT Int. Appl., 10 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002007736	A1	20020131	WO 2001-IB1313	20010723
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	IN 2000MU00687	A	20060303	IN 2000-MU687	20000724
PRAI	IN 2000-MU687	A	20000724		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 13 1-6 an ab

L3 ANSWER 1 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 147:79396 CA

AB The present invention concerns a process for the purification of macrolide antibiotics. More specifically it concerns a process for the purification of macrolide antibiotics that result in a white powder. The powder remains white also after some time of storage. The process of the present invention is performed by dissolving the macrolide antibiotics, e.g. com. vancomycin hydrochloride, in water and subjecting the solution to ultrafiltration with a membrane having nominal retention lower than 30,000 Da, preferably of 10,000 Da. The purified solution is preferably concentrated

by

reverse osmosis and then lyophilized at the optimized conditions of pressure and temperature to obtain a white powder.

L3 ANSWER 2 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 145:69954 CA

AB The azithromycin lyophilized powder for injection comprises azithromycin as active ingredient, HCl or lactobionic acid as a solution adjuvant, and a stabilizer, wherein the molar ratio of azithromycin to HCl or lactobionic acid is 1:(1.5-2.5); and the stabilizer is sodium sulfite (in an amount of 1-4.5% of the weight of azithromycin, the same below), EDTA-2Na (0.1-0.2%), polyethylene glycol 400 (150-250%) or a combination thereof.

L3 ANSWER 3 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 145:14751 CA

AB The invention provides among other things a stable, sterile pharmaceutical formulation comprising lyophilized azithromycin and ethanol. The invention also provides a method of producing a stable, sterile pharmaceutical product comprising lyophilized azithromycin. The invention also provides a pharmaceutical dosage form comprising the pharmaceutical formulation, as well as a method of treating a disease in a patient comprising administering a solution of the pharmaceutical formulation to a patient.

L3 ANSWER 4 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 144:94346 CA

AB This invention pertains to the enhanced delivery of orally administered pharmaceutical agents and methods, dosage forms and devices thereof. In particular, the invention is directed to methods including providing a low solubility drug having a pKa between about 6 and about 9; dissolving the low solubility drug in an aqueous solution, wherein a pH of the aqueous solution is less than

about 6.0; dissolving a hydrophilic polymer in the aqueous solution, wherein the

weight ratio of the hydrophilic polymer to the low solubility drug is less than or

equal to about 0.15; lyophilizing the aqueous solution to obtain a lyophilized powder. HPMC was an optimal hydrophilic polymer for preventing drug (ciprofloxacin-HCl) precipitation

L3 ANSWER 5 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 143:312016 CA

AB The invention provides among other things a stable, sterile pharmaceutical formulation comprising about 300 to 700 mg of lyophilized azithromycin and about 0.003 to 3.0% of ethanol. The invention also provides a method of producing a stable, sterile pharmaceutical product comprising lyophilized azithromycin, as well as a method of treating pneumonia or pelvic inflammatory disease in a patient by administering a solution of the lyophilized formulation.

L3 ANSWER 6 OF 6 CA COPYRIGHT 2007 ACS on STN

AN 136:139859 CA

AB Azithromycin is a macrolide antibiotic used for treating infections. This is available in a solid oral dosage form. It is desirable to have a clear liquid formulation also for treating severe infections by i.v.

administration of the drug. Currently, it is not possible to manufacture liquid

preparation which is ready to use. As it is not soluble in water or other known

solvents, for this purpose, it is being marketed as lyophilized preparation which is reconstituted prior to use. According to present invention, it is found that it is soluble in water at pH 5.0. The change in pH can be obtained by adding citric acid in a desired concentration. However, this solution is not stable, and ppts. are seen over the time. According to the present invention, this solution is stabilized by addition of sodium salts like sodium hydroxide, thereby changing its pH from 5.0 to 7.0. The solution so prepared remains clear and is stable for a longer period.